The short version of visceral adiposity fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-17. Anything still debated is marked as such rather than presented as settled.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
====== Latin America ====== Drug war policies in Latin America and the Caribbean have led to more violence, higher incarceration rates, health crises, and deeper poverty, while undermining trust in institutions and worsening inequality. There is increasing support for shifting toward drug policies that focus on sustainable development and human rights instead of punitive measures.
In 1996, it became a contract research organization (CRO) for the biopharmaceutical sector and entered into collaboration with SmithKline Beecham biologicals (Rixensart, Belgium) for the production of recombinant proteins for phase I, II and III clinical trials. In addition to its pharmaceutical manufacturing activities, Eurogentec became a service company for the biotechnical research industry and university laboratories. In 1999, Eurogentec acquired Oswel Research Product Ltd. a biotechnology company based in Southampton, Great Britain and specialized in the synthesis of chemically modified and complex oligonucleotides and their analogues (DNA, RNA, PNA). In 2002, Eurogentec acquired Wita Proteomics, a company specialized in proteomics services, based in Berlin (Germany). A few months later, Eurogentec installed its US office in San Diego for the production of oligonucleotides (EGT NA).
=== Pharmacodynamics === Gabapentinoids are high affinity ligands of the α2δ protein that was first described as an auxiliary subunit of certain voltage-gated calcium channels (VGCC). All of the known pharmacological actions of gabapentinoids require binding at this site. There are two drug-binding α2δ subunits, α2δ-1 and α2δ-2, and most gabapentinoids show similar affinity for (and hence lack of selectivity between) these two sites. In most cases, gabapentinoid drugs do not seem to directly alter the action of VGCC and instead reduce the release of certain excitatory neurotransmitters. (However, see). The gabapentinoid drugs do not bind significantly to other known drug receptors and so the α2δ VGCC subunit has been called the gabapentin receptor. Recently, the same α2δ-1 protein has been found closely associated not with VGCCs but with other proteins such as presynaptic NMDA-type glutamate receptors, cell adhesion molecules such as thrombospondin and others. Gabapentinoids alter the function of these additional α2δ binding proteins, and these have been proposed as mediators of drug actions. Despite the fact that gabapentinoids are GABA analogues, gabapentin and pregabalin do not bind to GABA receptors, do not convert into GABATooltip γ-aminobutyric acid or GABA receptor agonists in vivo, and do not modulate GABA transport or metabolism. Conversely, GABA does not bind appreciably to the α2δ protein. Furthermore, gabapentinoids do not act directly as inhibitors or blockers of VGCC.
Sources: en.wikipedia.org
== Carboxylation in biochemistry == Food chains usually originate from carboxylation that couples carbon dioxide to a sugar. The process is usually catalysed by the enzyme RuBisCO. Ribulose-1,5-bisphosphate carboxylase/oxygenase, the enzyme that catalyzes this carboxylation, is possibly the single most abundant protein on Earth.
Primary prevention to protect the normal line and strengthen the flexible line of defense. Secondary prevention to strengthen internal lines of resistance, reducing the reaction, and increasing resistance factors. Tertiary prevention to readapt and stabilize and protect reconstitution or return to wellness following treatment.
== History == In 1983, pioneers of glutathione research, Mary E. Anderson and Alton Meister, were the first to report on the ability of GGC to augment cellular GSH levels in a rat model. Intact GGC, which was synthesised in their own laboratory, was shown to be taken up by cells, bypassing the rate-limiting step of the GCL enzyme to be converted to glutathione. Control experiments with combinations of the constituent amino acids that make up GGC, including L-glutamic acid and L-cysteine, were ineffective. Since this initial work, only a few studies using GGC were performed due to the fact that there was no commercial source of GGC on the market. Subsequently, GGC has become commercially available and studies investigating its efficacy have commenced.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.